[Secondary exposure to hormonal drugs]

Area of Science:

• Endocrinology
• Pharmacology
• Toxicology

Background:

• Hormonal therapies are common treatments for various conditions, including menopausal symptoms.
• Transdermal drug delivery systems are frequently used for hormonal medications.
• Secondary exposure to transdermal hormones presents potential health risks to non-target individuals.

Purpose of the Study:

• To raise awareness regarding the risks of secondary exposure to transdermal hormone-containing drugs.
• To highlight adverse events observed in humans and animals due to unintended hormone absorption.

Main Methods:

• Review of spontaneous reports of suspected adverse events related to transdermal hormone therapy.
• Analysis of clinical signs documented in human and animal cases of secondary exposure.

Main Results:

• Human clinical signs included precocious puberty, virilization, accelerated growth, alopecia, fetal death, and infertility.
• Animal clinical signs encompassed persistent estrus, poor growth, and birth defects.
• Evidence suggests secondary exposure is a potential cause of these adverse events.

Conclusions:

• Secondary exposure to transdermal hormone drugs necessitates careful consideration during prescription.
• Clinicians and pet owners should be aware of these risks as a possible cause of unexplained clinical signs in humans and animals.
• Further vigilance is required to mitigate risks associated with transdermal hormone therapy.